20,500 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp acquired a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 20,500 shares of the company's stock, valued at approximately $527,000.

A number of other institutional investors have also made changes to their positions in NAMS. Deerfield Management Company L.P. Series C grew its stake in shares of NewAmsterdam Pharma by 378.4% during the fourth quarter. Deerfield Management Company L.P. Series C now owns 4,314,340 shares of the company's stock worth $110,879,000 after purchasing an additional 3,412,590 shares during the period. Jennison Associates LLC grew its stake in shares of NewAmsterdam Pharma by 291.9% during the fourth quarter. Jennison Associates LLC now owns 3,998,541 shares of the company's stock worth $102,763,000 after purchasing an additional 2,978,263 shares during the period. Wellington Management Group LLP grew its stake in shares of NewAmsterdam Pharma by 2,410.4% during the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after purchasing an additional 2,222,900 shares during the period. Capital International Investors acquired a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth $53,007,000. Finally, Alliancebernstein L.P. acquired a new stake in shares of NewAmsterdam Pharma during the fourth quarter worth $47,752,000. 89.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director James N. Topper purchased 4,005 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were bought at an average cost of $21.02 per share, for a total transaction of $84,185.10. Following the completion of the acquisition, the director now directly owns 3,012,434 shares in the company, valued at approximately $63,321,362.68. This trade represents a 0.13% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Louise Frederika Kooij sold 150,000 shares of the business's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares in the company, valued at approximately $305,550. This trade represents a 90.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 20.84% of the company's stock.

Wall Street Analyst Weigh In

NAMS has been the subject of a number of analyst reports. Wall Street Zen cut NewAmsterdam Pharma from a "hold" rating to a "sell" rating in a research note on Thursday. Scotiabank boosted their target price on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Thursday, February 27th. Royal Bank of Canada reissued an "outperform" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a research note on Monday, March 3rd. Finally, Needham & Company LLC decreased their target price on NewAmsterdam Pharma from $42.00 to $40.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $43.00.

NewAmsterdam Pharma Stock Performance

NASDAQ:NAMS traded down $0.67 on Friday, reaching $17.61. The company's stock had a trading volume of 274,673 shares, compared to its average volume of 639,119. NewAmsterdam Pharma has a 1-year low of $14.06 and a 1-year high of $27.29. The firm has a market cap of $1.93 billion, a PE ratio of -9.37 and a beta of 0.01. The business's 50-day moving average price is $18.58 and its two-hundred day moving average price is $21.23.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by ($0.04). The firm had revenue of $2.98 million during the quarter, compared to the consensus estimate of $1.46 million. As a group, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.